(PR-inside.com)
KVISTGAARD, Denmark, May 29, 2013 - Bavarian Nordic A/S (OMX: BAVA) announcedtoday that promising data from a Phase 2 trial of its CV-301 cancerimmunotherapy candidate in patients with resected metastatic colorectal cancerwere recently published in the Annals of Surgery. In a study conducted at DukeUniversity, 74 patients who were disease free after surgical resection ofmetastatic colon cancer received chemotherapy* followed by immunotherapy withCV-301 (formerly designated as PANVAC-VF) either as CV-301 modified dendriticcells or in combination with GM-CSF. Compared to a group of contemporary controlpatients who were matched for key clinical features and had similar surgery andchemotherapy, the overall survival of ..
More...
KVISTGAARD, Denmark, May 29, 2013 - Bavarian Nordic A/S (OMX: BAVA) announcedtoday that promising data from a Phase 2 trial of its CV-301 cancerimmunotherapy candidate in patients with resected metastatic colorectal cancerwere recently published in the Annals of Surgery. In a study conducted at DukeUniversity, 74 patients who were disease free after surgical resection ofmetastatic colon cancer received chemotherapy* followed by immunotherapy withCV-301 (formerly designated as PANVAC-VF) either as CV-301 modified dendriticcells or in combination with GM-CSF. Compared to a group of contemporary controlpatients who were matched for key clinical features and had similar surgery andchemotherapy, the overall survival of ..
More...